University of Duisburg-Essen Medical School
Welcome,         Profile    Billing    Logout  
 3 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schuler, Martin
GALAXIES LUNG-201, NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
340
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
10/25
10/28
Neopredict-lung, NCT04205552 / 2019-002478-29: Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients

Checkmark Data from NEOpredict study for resectable NSCLC
Dec 2022 - Dec 2022: Data from NEOpredict study for resectable NSCLC
Recruiting
2
90
Europe
Nivolumab 10 MG/ML Intravenous Solution, Relatlimab 10 MG/ML Intravenous Solution
University Hospital, Essen
NSCLC Stage II, NSCLC, Stage IIIA, NSCLC, Stage I
03/25
06/25
NCT05825625: NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Recruiting
2
35
Europe
Atezolizumab, Tecentriq, Tiragolumab, no other name available
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Roche Pharma AG
Non-small Cell Lung Cancer
11/29
02/30
GDFATHER, NCT04725474 / 2020-002103-19: First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer

Active, not recruiting
1/2
274
Europe
visugromab (CTL-002)
CatalYm GmbH, CatalYm GmbH
Solid Tumor, Adult
10/25
10/27
NCT06586515: A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting
1
530
Europe, Canada, Japan, US
LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
Eli Lilly and Company, Loxo Oncology, Inc.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
03/29
03/29
DigiNet, NCT05818449: Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation

Active, not recruiting
N/A
850
Europe
DigiNet intervention
University of Cologne, Gemeinsamer Bundesausschuss (G-BA), AOK Rheinland/Hamburg, AOK Nordwest, BARMER, University Hospital, Essen, Charite University, Berlin, Germany, Berlin Institute of Health, Helios Klinikum Emil von Behring, University Hospital Carl Gustav Carus, Deutsche Krebsgesellschaft e.V., Berufsverband der Niedergelassenen Hämatologen und Onkologen in Deutschland e.V., AOK Bundesverband, FOM Hochschule für Oekonomie und Management, University Medicine Greifswald, Technische Universität Dresden
Non-small Cell Lung Cancer Stage IV
03/25
03/25

Download Options